InnoCare Pharma has been granted a patent for a compound used as TRK inhibitors in pharmaceutical compositions to treat diseases like cancers. The compound, isomers, prodrugs, solvates, stable isotopic derivatives, or salts are covered under the patent. GlobalData’s report on InnoCare Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights InnoCare Pharma Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on InnoCare Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. InnoCare Pharma's grant share as of February 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.

The granted patent (Publication Number: US11878987B2) discloses a compound represented by formula I, along with its isomers, prodrugs, solvates, stable isotopic derivatives, or pharmaceutically acceptable salts. The compound is characterized by specific structural features, including the selection of L1, L2, and L3 groups, as well as the substituents R1-R7, G1, and m. The patent excludes certain compounds (1 to 7) from the scope of the invention, emphasizing the unique structural requirements for the claimed compound.

Furthermore, the patent details variations of the compound based on different combinations of L1, L2, and L3 groups, as well as the substituents R1-R7, G1, and m. These variations are designed to target TRK-mediated diseases such as hematological malignancies, lung cancer, breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, and gliomas. The patent also covers pharmaceutical compositions containing the disclosed compound and methods for treating TRK-mediated diseases by administering the compound or its derivatives to patients in need of such treatment. The patent's focus on specific structural characteristics and therapeutic applications highlights the potential for developing novel treatments for a range of diseases mediated by TRK proteins.

To know more about GlobalData’s detailed insights on InnoCare Pharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies